By Sherri Oslick --
About
Court Report: Each week we will report briefly on recently filed
biotech and pharma cases, and a few interesting cases will be selected
for periodic monitoring.
Ortho-McNeil Pharmaceutical, Inc. v. Apotex, Inc.
1:07-cv-04050; filed July 18, 2007 in the Northern District of Illinois
Infringement of U.S. Patent No. RE39,221 ("Composition Comprising a Tramadol Material and Acetaminophen and Its Use," issued August 1, 2006) following a paragraph IV certification as part of Apotex's filing of an ANDA to manufacture a generic version of Ortho-McNeil's Ultracet® (tramadol hydrochloride and acetaminophen, used to treat acute pain). View the complaint here.
Shire US Inc. et al. v. Johnson Matthey Inc. et al.
2:07-cv-02958; filed July 18, 2007 in the Eastern District of Pennsylvania
Declaratory judgment of noninfringement of U.S. Patent No. 6,096,760 ("Solid alpha-Phenyl-2-Piperidine Acetate Free Base, Its Preparation and Use in Medicine," issued August 1, 2000) based on Shire's manufacture and sale of its Daytrana (methylphenidate transdermal system). View the complaint here.
UCB Societe Anonyme et al v. Cobalt Pharmaceuticals, Inc.
1:07-cv-01630; filed July 13, 2007
Infringement of U.S. Patent No. 4,943,639 ("(S)-Alpha-Ethyl-2-Oxo-1-Pyrrolidineacetamide," issued July 24, 1990) following a paragraph IV certification as part of Cobalt's filing of an ANDA to manufacture a generic version of UCB's Keppra® (levetiracetam, used to treat epilepsy). View the complaint here.
Sepracor Inc. v. Barr Laboratories Inc.
1:07-cv-00438; filed July 12, 2007
Infringement of U.S. Patent Nos. 5,362,755 ("Method for Treating Asthma Using Optically Pure (R)-albuterol," issued November 8, 1994), 5,547,994 (same title, issued August 20, 1996), 5,760,090 (same title, issued June 2, 1998), 5,844,002 ("Method for Inducing Bronchodilation Using Optically Pure R(-) albuterol," issued December 1, 1998), and 6,083,993 ("Method for Treating Bronchospasm Using Optically Pure R(-) albuterol," issued July 4, 2000) following a paragraph IV certification as part of Barr's filing of an ANDA to manufacture a generic version of Sepracor's Xopenex® inhalation solutions (levalbuterol hydrochloride, used to treat asthma). View the complaint here.
Novartis Corp. et al. v. Dr. Reddy's Laboratories, Inc. et al.
2:07-cv-03221; filed July 12, 2007 in the District Court of New Jersey
Infringement of U.S. Patent No. 6,162,802 ("Synergistic Combination Therapy Using Benazepril and Amlodipine for the Treatment of Cardiovascular Disorders and Compositions Therefor," issued December 19, 2000) following a paragraph IV certification as part of Dr. Reddys' filing of an ANDA to manufacture a generic version of Novartis' Lotrel® (amlodipine besylate/benazepril hydrochloride, used to treat hypertension). View the complaint here.
Novo Nordisk A/S v. Sanofi-Aventis U.S. LLC et al.
3:07-cv-03206; filed July 10, 2007 in the District Court of New Jersey
Infringement of U.S. Patent No. 7,241,278 ("Injection Device," issued July 10, 2007) based on defendants' sale or anticipated sale of its SoloStar prefilled disposable insulin injection device ("pen") for use by patients in the treatment of diabetes. View the complaint here.
Comments